Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Brief Summary: This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab, Placebo
B: Arm Label: Part A: Atorvastatin 20 mg => Placebo; Type: OTHER; Interventions: Drug: Atorvastatin, Drug: Placebo to Atorvastatin | Arm Label: Part A: Placebo => Atorvastatin 20 mg; Type: OTHER; Interventions: Drug: Atorvastatin, Drug: Placebo to Atorvastatin | Arm Label: Part B: Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Other: Placebo to Evolocumab | Arm Label: Part B: Evolocumab; Type: EXPERIMENTAL; Interventions: Other: Placebo to Ezetimibe, Drug: Evolocumab | Arm Label: Part C: Open-label Evolocumab; Type: EXPERIMENTAL; Interventions: Drug: Evolocumab | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Part A: Atorvastatin 20 mg => Placebo, Part A: Placebo => Atorvastatin 20 mg | Intervention Type: DRUG; Name: Placebo to Atorvastatin; Assigned to Arm(s): Part A: Atorvastatin 20 mg => Placebo, Part A: Placebo => Atorvastatin 20 mg | Intervention Type: OTHER; Name: Placebo to Ezetimibe; Assigned to Arm(s): Part B: Evolocumab | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Part B: Ezetimibe | Intervention Type: OTHER; Name: Placebo to Evolocumab; Assigned to Arm(s): Part B: Ezetimibe | Intervention Type: DRUG; Name: Evolocumab; Assigned to Arm(s): Part B: Evolocumab, Part C: Open-label Evolocumab
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: cohort 3; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: cohort 4; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: cohort 5; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Intervention Type: DRUG; Name: REGN727; Assigned to Arm(s): Cohort 1, Cohort 2, cohort 3, cohort 4, cohort 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, cohort 3, cohort 4, cohort 5
D: Arm Label: Bococizumab (PF-04950615; RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615; RN316) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615; RN316); Assigned to Arm(s): Bococizumab (PF-04950615; RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo

Answer: D